deltatrials
Completed PHASE3 NCT00091663

A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

A Multicenter, Open-Label, Phase IIIb Trial of Tarceva (Erlotinib Hydrochloride) in Patients With Advanced Non-Small Cell Lung Cancer

Sponsor: Genentech, Inc.

Conditions Lung Cancer Non-small-cell Lung Carcinoma
Interventions Tarceva (erlotinib HCl)
Updated 6 times since 2017 Last updated: Feb 28, 2014 Started: Aug 31, 2004 Completion: Aug 31, 2005

A PHASE3 clinical study on Lung Cancer and Non-small-cell Lung Carcinoma, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abingdon, United States, Anchorage, United States, Annapolis, United States, Arlington, United States, Arlington Heights, United States, Asheville, United States, Athens, United States, Austin, United States, Baltimore, United States, Baton Rouge, United States and 75 more location s